Abstracts tagged "interferon"

Abstract Number: L01 • ACR Convergence 2024
Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases
Matthew Martin¹, Erik Wilker¹, Diana Gikunju¹, Usha Narayanan¹, Unnati Pandya¹, Vijetha Prakash¹, Ashley Edwards¹, Sameer Kawatkar¹, Tenghui Chen¹, Ragunath Chandran¹, Sai Sunder¹, Sumathi Biradar¹, Joerg Distler², Alexandra Joseph¹, Stephanos Ioannidis¹ and Bhavatarini Vangamudi¹, ¹Exo Therapeutics, Cambridge, MA, ²Exo Therapeutics, Düsseldorf, Germany
Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
Abstract Number: 0633 • ACR Convergence 2024
Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus
Wenyan Miao¹, Digna de Bruin², Cedric Arisdakessian¹, Jannik Rousel², Jared Steranka¹, Matthijs Moerland², Eric Jacobson¹, Mehrnaz Gharaee-Kermani³, Liyang Diao¹, Craig Dobry³, Nafeeza Hafeez¹, Brian Desrosiers¹, J. Michelle Kahlenberg³, Heike Keilhack¹, Robert Rissmann², Keith M Wilcoxen¹ and Tessa Niemeyer-van der Kolk², ¹Rome Therapeutics, Boston, MA, ²Centre for Human Drug Research, Leiden, Netherlands, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Long Interspersed Element-1 (LINE-1) retrotransposon encodes for two proteins, ORF1p and ORF2p. ORF1p is a chaperone protein while ORF2p contains reverse transcriptase (RT) and…
Abstract Number: 1537 • ACR Convergence 2024
Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases
Kelly A. Pike¹, Nadine Fradet¹, Samuel Gaudreault¹, Alexander M Skeldon², Ramsay E. Beveridge², Patrick Cyr², Nicolas Sgarioto², Philippe Le Gros³, Eleftheria Seliniotakis², Valerie Dumais², Jacklyn Smith², James I.P Stewart², Mehrnaz Gharaee-Kermani⁴, Michelle J Kahlenberg⁴ and Michael A. Crackower², ¹Ventus Therapeutics, Saint-Laurent, QC, Canada, ²Ventus Therapeutics, Saint-Laurent, Canada, ³Ventus Therapeutics, Montreal, QC, Canada, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Cyclic GMP-AMP synthase (cGAS) is a nucleic acid sensor that plays a central role in anti-viral responses. Following the detection of intracellular double-stranded DNA,…
Abstract Number: 1828 • ACR Convergence 2024
SSc Fibroblasts Trigger a Systemic Type I Interferon Response in SSc Patients Through Canonical TGF-β Receptor Signalling
Christopher Wasson¹, Stefano Di Donato², Rebecca Ross³, Vishal Kakkar⁴ and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ³Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁴LIRMM University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis is an autoimmune disease which is characterized by fibrosis of the skin and the internal organs with variable severity. Type I interferon…
Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Cuiling Fan¹, Shixian Chen² and Juan Li¹, ¹Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), ²Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
Abstract Number: 1553 • ACR Convergence 2024
Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)
Torsten Witte¹, Ruth Fernandez Ruiz², Nadezda Abramova³, Dominika Weinelt³, Flavie Moreau⁴, Lena Klopp-Schulze⁵, Jamie Shaw⁶, Deborah Denis⁷ and Joerg Wenzel⁸, ¹Dept of Immunology and Rheumatology, Hannover, Germany, ²Global Clinical Development, EMD Serono, Billerica, MA, ³Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁴Global Biostatistics, EMD Serono, Billerica, MA, ⁵Quantitative Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁶Companion Diagnostics and Biomarker Strategy, EMD Serono, Billerica, MA, ⁷EMD Serono, Rockland, MA, ⁸Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany
Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…
Abstract Number: 1831 • ACR Convergence 2024
Role of Long Non-Coding RNA H19 in Mediating Skin Fibrosis in Systemic Sclerosis
Begoña Caballero-Ruiz¹, Christopher Wasson², Rebecca Ross³ and Francesco Del Galdo², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is an immune driven condition leading to skin fibrosis, as well as internal organs. Dermal fibroblasts are the key cellular elements…
Abstract Number: 0815 • ACR Convergence 2024
Interferon-stimulated Gene Expression in Non-lesional Skin Is Similarly Elevated in Incomplete SLE and SLE
Svenja Henning¹, Lam Tsoi², Benjamin Klein², Celine Berthier², Joseph Kirma², Rachael Wasikowski³, Gilles Diercks⁴, Barbara Horvath¹, Hendrika Bootsma⁵, Johann Gudjonsson², Johanna Westra⁴, Karina de Leeuw⁶ and J. Michelle Kahlenberg², ¹University of Groningen, Groningen, Netherlands, ²University of Michigan, Ann Arbor, MI, ³Michigan, Dept. of Dermatology, Ann Arbor, MI, ⁴University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ⁶University Medical Center Groningen, Groningen, Groningen, Netherlands
Background/Purpose: Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria are referred to as incomplete SLE (ILE). These patients are…
Abstract Number: 1556 • ACR Convergence 2024
Efficacy and Safety of Anifrolumab Across Organ Domains of Systemic Lupus Erythematosus. A Systematic Review and Meta-Analysis
Mohammad Taha¹, Yomna W Mahmoud¹, Mohammad Ramadan¹, sarah nasir¹, Mariam salah¹, Yassin shenawy², doaa gadelrab¹ and Muhammad abuawwad¹, and ARC team, ¹Cairo university, Cairo, Egypt, ²cairo, cairo, Egypt

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. Anifrolumab is a monoclonal antibody that antagonizes type I interferon receptors,…
Abstract Number: 1837 • ACR Convergence 2024
Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment
Addison Pacheco¹, Zoya Qaiyum², Fataneh Tavasolian³, Melissa Lim⁴, Michael Tang¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto, ON, Canada, ³Krembil Research Institute - the University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Our study aims to discriminate immune profiles between secukinumab responders (SEC-R) and nonresponders (SEC-NR) in axial spondyloarthritis (axSpA) patients before biologic treatment.Methods: CD45RO+CD45RA-CD4+ T…
Abstract Number: 0839 • ACR Convergence 2024
Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity
Haoyu Pan, Xiaohan Wei, Jinyi Qian, Shuyi Yu, Zhixia Yang, Zetao Ding, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized with the presence of pathogenic antiphospholipid antibodies (aPL) by autoreactive B cells. However, it remains…
Abstract Number: 1646 • ACR Convergence 2024
A Novel E3 Ligase of GILZ: Validation of a Steroid-sparing Therapeutic Target in SLE
Iolanda Miceli¹, Rochelle Sherlock², Pamela Hall², IanIan Cheang², Akshay D'Cruz³, Taylah Bennett², Terry Lim Kam Sian², Rangi Kandane-Rathnayake⁴, Eric Morand⁵ and Sarah Jones², ¹Monash University, Glen Iris, Victoria, Australia, ²Monash University, Melbourne, Australia, ³Monash University, Me, Australia, ⁴Monash University, Clayton, Victoria, Australia, ⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: SLE is primarily mediated by B cell dysregulation on a background of type I interferon (IFN) activation. This multi-faceted nature of immune defects in…
Abstract Number: 2077 • ACR Convergence 2024
Comparison of Janus Kinase Inhibitors to Block the Type I and II Interferon Pathways in Human Myoblasts
Travis Kinder and James Inglese, National Institutes of Health, Rockville, MD
Background/Purpose: The family of Janus kinases (JAK1, JAK2, JAK3, TYK2) mediate signal transduction from cytokine receptors through phosphorylation and activation of intracellular signaling pathways and…
Abstract Number: 0887 • ACR Convergence 2024
Identification of Rare Variants in Lupus-causing Genes in a Mixed Paediatric and Adult Connective Tissue Disease Cohort
Anastasia-Vasiliki Madenidou¹, Gillian Rice², Terence Garner³, Sarah Dyball⁴, Alice Chieng⁵, Ben Parker⁶, Tracy Briggs⁷, Adam Stevens³ and Ian Bruce⁸, ¹Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ²Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, ³Division of Developmental Biology and Medicine, Faculty of Biology, Medicine and Health, University of Manchester and Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, ⁴Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom, ⁵Department of Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, Manchester, United Kingdom, ⁶Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁷Division of Evolution, Infection and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, ⁸Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Connective tissue diseases (CTDs) are a family of heterogeneous autoimmune diseases with overlapping clinical features. Not all patients with features suggestive of a mendelian…
Abstract Number: 1706 • ACR Convergence 2024
Multi-omic Study in Patients with SITRAME Syndrome
Yixiang Yves-Jean Zhu¹, Angèle Soria², Thomas Moreau³, Guilaine Boursier⁴, Vincent Bondet⁵, Françoise Donnadieu⁶, Clara Cretet⁷, Aness Haddouche⁷, Carine Schmidt³, Diego Bletry³, Emmanuelle Amsler², Annick Barbaud², Farah Rahal⁵, Yannick Chantran⁸, Margaux Cescato³, François Maillet⁹, Anne-Sophie Korganow¹⁰, Benjamin Chaigne¹¹, Yannick Dieudonné¹⁰, Guillaume Lefevre¹², Makoto Miyara⁷, Vivien Beziat¹³, Caroline Deswarte¹³, Michael White⁶, Sophie Georgin-lavialle¹, Darragh duffy⁵ and Mathieu Paul Rodero³, ¹Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²Sorbonne Université, Department of dermatology and allergology, Tenon hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ³Université Paris CIté, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Faculté des Saint-Pères, Paris, France, ⁴University of Montpellier, Montpellier, ⁵Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, ⁶Pasteur Institut, Laboratoire d'épidémiologie et analyse des maladies infectieuses, Paris, France, ⁷Sobonne University, Centre d'Immunologie et des Maladies Infectieuses, Paris, France, ⁸Departmen of Biological Immunology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁹AP HP, Paris, France, ¹⁰University of Strasbourg, Department of Clinical Immunology and Internal Medicine, Nouvel Hôpital Civil, Strasbourg, France, ¹¹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France, ¹²CHU Lille, Institut d’Immunologie, Lille, France., Lille, France, ¹³IMAGINE Institut, Human Genetics of Infectious Diseases Laboratory, Paris, France
Background/Purpose: The SITRAME syndrome (Systemic Inflammatory Trunk Recurrent Acute Macular Eruption) is a newly described inflammatory entity affecting adult patients with no family history (Soria…

1
2
3
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].